New England Biolabs Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:New England Biolabs Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014177
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
New England Biolabs Inc (NEB) is a life science company that develops recombinant and native enzymes for genomic research. The company offers products such as competent cells, DNA plasmids, protein tools, buffers and strains, and others. It has applications in cloning and synthetic biology, RNA analysis, DNA amplification and PCR, DNA modification, library preparation for next generation sequencing and epigenetic, among others. It also provides interactive tools for research and experimental designs. The company has its presence with subsidiaries in Canada, China, France, Germany, Japan, Singapore and the UK. It offers its products globally through a channel of network distributors. NEB is headquartered in Ipswich, Massachusetts, the US.

New England Biolabs Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
New England Biolabs Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
New England Biolabs Inc, Medical Devices Deals, 2011 to YTD 2017 8
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
New England Biolabs Enters into Co-Development Agreement with Directed Genomics 10
Beckman Coulter Partners with New England Biolabs 11
SwitchGear Genomics Enters Into Co-Development Agreement With New England Biolabs 12
New England Biolabs Enters Into Co-Marketing Agreement With Rubicon Genomics 13
New England Biolabs Enters Into Co-Marketing Agreement With Imperial Life Sciences 14
Licensing Agreements 15
New England Biolabs Enters Into Licensing Agreement With Synthetic Genomics 15
SomaLogic Enters Into Licensing Agreement With New England Biolabs 16
New England Biolabs Enters Into Licensing Agreement With Sequenom 17
New England Biolabs Inc – Key Competitors 18
New England Biolabs Inc – Key Employees 19
New England Biolabs Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 22
Product News 22
Nov 07, 2017: New England Biolabs Launches NEBNext Ultra II FS Kit for Robust Enzyme-based DNA Fragmentation and Library Preparation with as Little as 100 pg of Input DNA 22
Jan 12, 2016: New England Biolabs Launches Environmentally-Friendly Monarch Kits for High-Quality DNA Purification 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
New England Biolabs Inc, Pharmaceuticals & Healthcare, Key Facts 2
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
New England Biolabs Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
New England Biolabs Inc, Medical Devices Deals, 2011 to YTD 2017 8
New England Biolabs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
New England Biolabs Enters into Co-Development Agreement with Directed Genomics 10
Beckman Coulter Partners with New England Biolabs 11
SwitchGear Genomics Enters Into Co-Development Agreement With New England Biolabs 12
New England Biolabs Enters Into Co-Marketing Agreement With Rubicon Genomics 13
New England Biolabs Enters Into Co-Marketing Agreement With Imperial Life Sciences 14
New England Biolabs Enters Into Licensing Agreement With Synthetic Genomics 15
SomaLogic Enters Into Licensing Agreement With New England Biolabs 16
New England Biolabs Enters Into Licensing Agreement With Sequenom 17
New England Biolabs Inc, Key Competitors 18
New England Biolabs Inc, Key Employees 19
New England Biolabs Inc, Subsidiaries 20

★海外企業調査レポート[New England Biolabs Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Companhia Energetica de Sao Paulo (CESP6)-エネルギー分野:企業M&A・提携分析
    Summary Companhia Energetica de Sao Paulo (CESP) is a state-owned integrated electric utility. It plans, constructs, and operates electric energy generation and commercialization systems. The company generates energy from hydro source. CESP owns power plants at at Rio Paran, Rio Paraibuna, and Rio J …
  • Trubnaya Metallurgicheskaya Kompaniya:企業の戦略・SWOT・財務情報
    Trubnaya Metallurgicheskaya Kompaniya - Strategy, SWOT and Corporate Finance Report Summary Trubnaya Metallurgicheskaya Kompaniya - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Sidney Kimmel Comprehensive Cancer Center-製薬・医療分野:企業M&A・提携分析
    Summary Sidney Kimmel Comprehensive Cancer Center (Sidney Kimmel) is a healthcare service provider that concentrates on diagnosis, treatment, and prevention of cancer. The center’s specialties include cancer diagnostic and treatment planning, blood and bone marrow cancers, cancer immunotherapy, brai …
  • Mednax Inc (MD)-製薬・医療分野:企業M&A・提携分析
    Summary Mednax Inc (Mednax) is a national medical group company, which operates a network of physician service providers. The company offers a wide range of neonatal, anesthesia, maternal-fetal, pediatric physician and subspecialty services. Its network includes other pediatric subspecialists compri …
  • Pact Group Holdings Ltd:企業の戦略・SWOT・財務情報
    Pact Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Pact Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Norsk Hydro ASA:企業のM&A・事業提携・投資動向
    Norsk Hydro ASA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Norsk Hydro ASA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Engie Brasil Energia SA (EGIE3):企業の財務・戦略的SWOT分析
    Engie Brasil Energia SA (EGIE3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Hoya Corporation:企業の戦略・SWOT・財務分析
    Hoya Corporation - Strategy, SWOT and Corporate Finance Report Summary Hoya Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Thundelarra Ltd (THX):企業の財務・戦略的SWOT分析
    Summary Thundelarra Ltd (Thundelarra) is a mining and mineral exploration company. The company acquires, explores and develops lead, zinc, silver, nickel, graphite, copper, gold and uranium prospects in Western Australia and the Northern Territory. Its projects include Red Bore Copper-Gold Project, …
  • Myriad Genetics Inc (MYGN):企業の製品パイプライン分析2018
    Summary Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, t …
  • Tempo Beverages Ltd.:企業の戦略・SWOT・財務情報
    Tempo Beverages Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tempo Beverages Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Orange Belgium (OBEL):企業の戦略的SWOT分析
    Orange Belgium (OBEL) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Hibu Group Limited:戦略・SWOT・企業財務分析
    Hibu Group Limited - Strategy, SWOT and Corporate Finance Report Summary Hibu Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Engie Energia Chile SA (ECL):企業の財務・戦略的SWOT分析
    Engie Energia Chile SA (ECL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Samsung Medison Co Ltd:企業の戦略的SWOT分析
    Samsung Medison Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Linamar Corporation:企業の戦略・SWOT・財務情報
    Linamar Corporation - Strategy, SWOT and Corporate Finance Report Summary Linamar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • QVC Inc:企業の戦略的SWOT分析
    QVC Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Nick Scali Ltd (NCK):企業の財務・戦略的SWOT分析
    Nick Scali Ltd (NCK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Olon SpA:製薬・医療:M&Aディール及び事業提携情報
    Summary Olon SpA (Olon), formerly Antibioticos SpA, a susbsidiary of P&R S.p.A. is a developer and producer of active pharmaceutical ingredients. The company offers products such as azacitidine, bezafibrate, ibuprofen sodium, acamprosate calcium, acebutolol hydrochloride, acitretin, thalidomide, aba …
  • GRP Limited (GRPLTD):企業の財務・戦略的SWOT分析
    GRP Limited (GRPLTD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆